Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study.
Brain imaging
Glutamate
Receptor
[11C]ITDM
mGluR1
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
04
10
2019
accepted:
22
12
2019
pubmed:
9
1
2020
medline:
30
12
2020
entrez:
9
1
2020
Statut:
ppublish
Résumé
Impairment of group I metabotropic glutamate receptors (mGluRs) results in altered glutamate signalling, which is associated with several neurological disorders including Huntington's Disease (HD), an autosomal neurodegenerative disease. In this study, we assessed in vivo pathological changes in mGluR1 availability in the Q175DN mouse model of HD using longitudinal positron emission tomography (PET) imaging with the radioligand [
Identifiants
pubmed: 31912442
doi: 10.1007/s12035-019-01866-5
pii: 10.1007/s12035-019-01866-5
pmc: PMC7118044
doi:
Substances chimiques
4-fluoroethoxy-N-(4-(6-(isopropylamino)pyrimidin-4-yl)-1,3-thiazol-2-yl)-N-methylbenzamide
0
Benzamides
0
Receptors, Metabotropic Glutamate
0
Thiazoles
0
metabotropic glutamate receptor type 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2038-2047Subventions
Organisme : FWO
ID : 11W2518N
Références
Hum Mol Genet. 2014 Apr 15;23(8):2030-42
pubmed: 24282028
J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52
pubmed: 12468889
Sci Signal. 2017 Dec 19;10(510):
pubmed: 29259100
J Biol Chem. 1998 Mar 6;273(10):5615-24
pubmed: 9488690
J Neurosci. 2010 Jan 6;30(1):316-24
pubmed: 20053912
PLoS One. 2015 Apr 10;10(4):e0123527
pubmed: 25859666
Neurosci Lett. 2001 Nov 9;313(3):129-32
pubmed: 11682144
PLoS One. 2016 Feb 09;11(2):e0148839
pubmed: 26859386
Neuroscience. 2007 Jun 29;147(2):354-72
pubmed: 17544587
J Med Chem. 2012 Dec 27;55(24):11042-51
pubmed: 23194448
J Biol Chem. 1992 Jul 5;267(19):13361-8
pubmed: 1320017
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
Mol Imaging Biol. 2019 Dec 2;:
pubmed: 31792838
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
Brain Struct Funct. 2015 Sep;220(5):3043-51
pubmed: 24969128
Br J Anaesth. 2002 Aug;89(2):287-93
pubmed: 12378669
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):574-95
pubmed: 20632969
Front Neurol. 2018 Jun 29;9:516
pubmed: 30013509
Pharmacol Rev. 2008 Dec;60(4):536-81
pubmed: 19112153
J Neurosci. 2012 Nov 21;32(47):16933-42a
pubmed: 23175844
J Neurosci. 1993 May;13(5):2001-12
pubmed: 8386753
PLoS One. 2012;7(12):e49838
pubmed: 23284626
Mol Brain. 2019 Apr 8;12(1):35
pubmed: 30961637
Pharmacol Rev. 2001 Mar;53(1):1-24
pubmed: 11171937
Neurosci Lett. 1998 Mar 6;244(1):29-32
pubmed: 9578137
J Neurochem. 2018 Oct;147(2):222-239
pubmed: 30028018
Neurobiol Dis. 2015 Jan;73:163-73
pubmed: 25160573
PLoS One. 2012;7(12):e50717
pubmed: 23284644
J Nucl Med. 2018 Nov;59(11):1722-1727
pubmed: 29794227
PLoS One. 2013 Jul 23;8(7):e69782
pubmed: 23936100
Lancet Neurol. 2011 Jan;10(1):83-98
pubmed: 21163446
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6480-5
pubmed: 9600992
Mol Biol Cell. 2009 Mar;20(5):1478-92
pubmed: 19144827
Expert Opin Ther Targets. 2014 Nov;18(11):1293-304
pubmed: 25118797
Neuroscience. 1994 Nov;63(2):363-79
pubmed: 7891852
PLoS One. 2018 Oct 26;13(10):e0206613
pubmed: 30365550
J Cereb Blood Flow Metab. 2014 Apr;34(4):606-12
pubmed: 24398932
Neuroimage. 2010 Nov 1;53(2):365-72
pubmed: 20600960
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Neuron. 2003 Jul 17;39(2):227-39
pubmed: 12873381
Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2602-7
pubmed: 15695335
Nat Rev Neurol. 2014 Apr;10(4):204-16
pubmed: 24614516
J Nucl Med. 2017 Apr;58(4):617-622
pubmed: 27856625
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
pubmed: 17519979
Mol Neurobiol. 2011 Feb;43(1):1-11
pubmed: 21153060